PCI Biotech Holding — M&A Activity 2016

Dec 13, 2016

PCI Biotech: Update on the existing pre-clinical research collaboration agreement with a top-10 large pharma company

PCI Biotech: Update on the existing pre-clinical research collaboration agreement with a top-10 large pharma company

Oslo, December 13, 2016 - PCI Biotech (OSE: PCIB), a cancer focused

biopharmaceutical company, reported today that the undisclosed top-10 pharma

company has notified PCI Biotech that they intend to extend the existing

research collaboration agreement, originally signed in September 2015, until the

end of 2Q 2017. The aim of the extension is to further evaluate the synergistic

effects of both parties' technology platforms, to determine whether PCI

Biotech's fimaNAc technology has the potential to enhance the therapeutic effect

of the partner's nucleic acid therapeutic compounds.

The pre-clinical research agreement covers evaluation of technological

compatibility and synergy based on in vitro studies. The pharma company is one

of the global leaders in nucleic acid therapeutics and is responsible for

funding and conducting the research. The companies will evaluate the data

generated in this research collaboration and explore the potential for a further

partnership based on this outcome. The extended evaluation period spans over six

months, but may be further extended.

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on development and

commercialisation of novel therapies for the treatment of cancer through its

innovative photochemical internalisation (PCI) technology platform.  PCI is

applied to three distinct anticancer paradigms: fimaChem (enhancement of

chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction

technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics

delivery).

Photochemical internalisation induces triggered endosomal release that is used

to unlock the true potential of a wide array of therapeutic modalities. The

company's lead fimaChem programme consists of a clinical Phase I/II clinical

study in bile duct cancer, an orphan indication with a high unmet need and

without approved products.  fimaVacc applies a unique mode of action to enhance

the essential cytotoxic effect of therapeutic cancer vaccines, which works in

synergy with several other state-of-the-art vaccination technologies.  fimaNAc

utilises the endosomal release to provide intracellular delivery of nucleic

acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major

bottlenecks facing this emerging and promising field.

Contact information:

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.

www.pcibiotech.com

Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.